ArticleFrontiers in immunology2026
Translating viral genetic data to PRRSV-2 cross-neutralization using machine learning.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Swine herd immunization through modified live vaccination or live virus inoculation is a core strategy for controlling porcine reproductive and respiratory syndrome (PRRS), one of the most economically important endemic diseases in the United States that is caused by PRRSV-2. While antigenically homologous PRRSV-2 viruses are expected to elicit better immunological cross-protection, questions remain as to how genetic similarity translates to the degree of cross-protection elicited between the immunizing strain and subsequent challenge virus. For PRRSV-2, virus neutralization (VN) assays are commonly used to approximate humoral immune responses and to assess cross-variant vaccine efficacy; however, these assays are labor-intensive and difficult to scale for rapid immunization planning. Methods: Here, we developed a machine learning-based predictive model for PRRSV-2 cross-neutralization using viral genetic sequence data to address this gap. Virus neutralization assays were performed across a panel of viral isolates and anti-sera, representing a variety of contemporary and vaccine-like PRRSV-2 variants. Our internal dataset comprised 219 cross-neutralization pairs involving nine viral isolates and 25 antisera generated from animals inoculated with six isolates (immunizing viruses). Neutralization titers were classified as above versus below average using mean standardized log Results: The best models, which utilized predictors from protein ectodomain features, effectively estimated whether a virus-antisera pair would exhibit above versus below average neutralization, achieving balanced accuracies of 87-92% on internal data, and 71-89% across three external VN datasets. Key predictors included amino acid properties in GP5 decoy epitope and hypervariable regions, residues within GP2-GP3 epitopes, and overall genetic distance. Conclusion: These models are publicly available through a web-based tool (https://stemma.shinyapps.io/PRRSLoom-NeutralizationPredictor/) for end-users to estimate the neutralization potential between genetically distinct PRRSV-2 viruses. Our integration of machine learning,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.